EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
EXELIXIS, INC.
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026
$62.68+0.45 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $16.28B
- P/E (TTM)
- 19.7
- Dividend yield
- –
EXELIXIS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross product revenues | $812.78M | $795.35M | $764.54M | $780.27M | $745.28M | $721.71M | $703.75M | $646.42M | $604.29M | $563.79M | $597.60M | $590.44M | 129.3% | +9.1% |
| Net product revenues | $573.03M | $554.98M | $546.58M | $542.93M | $520.01M | $513.28M | $515.23M | $478.06M | $437.58M | $378.52M | $429.34M | $426.50M | 91.1% | +10.2% |
| CABOMETYX | $570.65M | $552.77M | $544.73M | $539.88M | $517.89M | $510.87M | $512.81M | $475.67M | $433.34M | $376.42M | $427.72M | $422.16M | 90.8% | +10.2% |
| License revenues | $59.81M | $56.95M | $66.36M | $56.24M | $49.30M | $42.48M | $49.34M | $60.24M | $194.99M | $44.68M | $45.23M | $42.37M | 9.5% | +21.3% |
| Collaboration revenues | $55.67M | $55.84M | $52.09M | $54.83M | $48.25M | $42.16M | $51.52M | $61.48M | $199.60M | $46.70M | $50.32M | $45.42M | 8.9% | +15.4% |
| COMETRIQ | $2.38M | $2.20M | $1.85M | $3.05M | $2.12M | $2.41M | $2.42M | $2.39M | $4.24M | $2.11M | $1.61M | $4.34M | 0.4% | +11.9% |
| Collaboration services revenues | -$4.15M | -$1.11M | – | -$1.41M | -$1.05M | -$316.00K | $2.18M | $1.24M | $4.61M | $2.03M | $5.09M | $3.06M | -0.7% | +293.3% |
| Discounts and allowances | -$239.76M | -$240.38M | – | -$237.34M | -$225.27M | -$208.43M | – | -$168.36M | -$166.71M | -$185.26M | – | -$163.95M | -38.1% | +6.4% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $578.36M | $558.55M | $551.96M | $546.46M | $524.77M | $517.18M | $519.12M | $481.46M | $440.48M | $381.94M | $432.66M | $429.61M | 92.0% | +10.2% |
| Europe | $46.01M | $39.57M | $39.46M | $44.97M | $37.03M | $32.71M | $41.29M | $51.08M | $190.56M | $35.70M | $38.68M | $36.02M | 7.3% | +24.2% |
| Japan | $4.32M | $12.70M | $7.25M | $6.33M | $6.46M | $5.56M | $6.35M | $7.00M | $6.14M | $7.59M | $8.31M | $6.29M | 0.7% | -33.1% |
From the segment and revenue-disaggregation notes of Exelixis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.